MRNA250502C30000
- 0.01
- 0.000.00%
Moderna Newsroom
TD Cowen Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $30
Redburn Atlantic Adjusts Moderna Price Target to $53 From $52, Maintains Neutral Rating
Bernstein Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $28
RBC Capital Maintains Sector Perform on Moderna, Lowers Price Target to $28
Berenberg Bank Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $30
Piper Sandler Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $69
UBS Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $70
Moderna Analyst Ratings
Evercore ISI Group Maintains In-Line on Moderna, Lowers Price Target to $32
A Quick Look at Today's Ratings for Moderna(MRNA.US), With a Forecast Between $30 to $40
Morgan Stanley Trims Price Target on Moderna to $31 From $32, Keeps Equalweight Rating
Citigroup Cuts Moderna Price Target to $32 From $40
Research Alert: Mrna: Mixed Q1 Results, 2025 Sales Guidance Maintained Pointing To Y/y Decline
Bernstein Adjusts Moderna Price Target to $28 From $39, Maintains Market Perform Rating
HSBC Upgrades Moderna(MRNA.US) to Buy Rating, Cuts Target Price to $49
BofA Securities Maintains Moderna(MRNA.US) With Sell Rating, Cuts Target Price to $26
TD Cowen Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $30
Wolfe Research Adjusts Moderna Price Target to $20 From $25, Keeps Underperform Rating
William Blair Maintains Moderna(MRNA.US) With Hold Rating
Leerink Partners Maintains Moderna(MRNA.US) With Sell Rating, Cuts Target Price to $23